Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.
Actively Recruiting
Researchers are evaluating the efficacy and safety of cariprazine in treating schizophrenia among adolescents aged 13 to 17 years. This international, multicenter study is designed as a randomized, double-blind, placebo-controlled trial to understand how cariprazine affects symptoms of schizophrenia in this younger population. Participants will be randomly assigned to receive either cariprazine capsules at doses of 1.5 mg or 4.5 mg once daily, or matching placebo capsules once daily. The treatment phase lasts for six weeks, during which participants take the assigned capsules orally every day. During the study, participants will be monitored regularly to assess changes in their schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also evaluate safety and tolerability throughout the trial. The main measurement is the change in PANSS total score from the start to the end of the six-week period. The study is designed to last until December 2026.
Actively Recruiting
Researchers are evaluating the efficacy and safety of milsaperidone as an add-on treatment for patients with Major Depressive Disorder MDD who have not responded adequately to current antidepressant therapy. This phase 3, randomized, double-blind, placebo-controlled study aims to compare milsaperidone with a placebo to better understand its potential benefits and risks in this patient population. Participants will be randomly assigned to receive either oral milsaperidone or a matching placebo. The study uses a parallel design and involves multiple centers. The treatment period lasts 6 weeks, during which participants take the assigned oral medication as adjunctive therapy to their existing antidepressant regimen. During the study, participants will be closely monitored with regular assessments including the Montgomery-Asberg Depression Rating Scale MADRS to measure changes in depressive symptoms from baseline. Safety and tolerability will also be evaluated throughout the trial. The total duration of participation corresponds with the 6-week treatment and ongoing safety assessments, concluding by March 2028.
Actively Recruiting
Researchers are evaluating the drug NBI-1117570 for its effects on behavioral and psychological symptoms in adults with schizophrenia who need inpatient hospitalization. This phase 2a study compares NBI-1117570 to a placebo to assess its efficacy, safety, tolerability, and how the drug is processed in the body. Participants will be randomly assigned to one of three groups a lower-dose NBI-1117570 group, a higher-dose NBI-1117570 group, or a placebo group. The drug and placebo are given orally. The study uses a parallel design with quadruple masking to maintain blinding. The primary treatment period lasts 35 days, after which safety and adverse events are monitored up to 49 days. During the study, participants will have assessments to measure changes in schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also track any treatment-emergent adverse events throughout the treatment and follow-up periods. The trial is sponsored by Neurocrine Biosciences and runs from February 2026 to August 2027.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of ITI-1284 as an additional treatment for adults with Generalized Anxiety Disorder GAD who have not had sufficient improvement from their current GAD medication. This study is a multicenter, randomized, double-blind, placebo-controlled trial focusing on patients diagnosed with moderate to severe GAD according to the DSM-5-TR criteria. Participants are randomly assigned to one of three groups to receive either ITI-1284 10 mg, ITI-1284 20 mg, or a matching placebo. All treatments are administered as once-daily sublingual tablets alongside their ongoing GAD therapy. The study treatment period lasts for six weeks, during which participants continue their existing GAD medication at stable doses. Throughout the study, participants will undergo assessments including the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression Scale-Severity CGI-S to measure anxiety symptoms and overall severity. The primary outcome is measured at week 6. Safety and tolerability are monitored closely during visits. The total duration of participation aligns with the six-week treatment period.
Actively Recruiting
Researchers are evaluating the drug ITI-1284 as a monotherapy treatment in patients diagnosed with moderate to severe Generalized Anxiety Disorder GAD who have not responded adequately to previous GAD treatments. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to assess the efficacy, safety, and tolerability of ITI-1284 in this patient population. Participants are randomly assigned to one of three groups ITI-1284 10 mg tablet, ITI-1284 20 mg tablet, or a matching placebo, all taken once daily by sublingual administration. The study compares these doses to placebo over a treatment period, with assessments planned at Week 6. During the study, participants will be monitored for changes in anxiety using the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression Scale-Severity CGI-S at Week 6. Safety and tolerability will also be evaluated. The total duration includes the screening, treatment, and follow-up periods leading up to the primary completion date in October 2027 and study completion in July 2028.